Title |
Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics Beyond EROOM’s Law
|
---|---|
Published in |
JACC: Basic to Translational Science, October 2017
|
DOI | 10.1016/j.jacbts.2017.09.002 |
Pubmed ID | |
Authors |
Gail A. Van Norman |
Abstract |
Eroom's law (Moore's law spelled backwards), describes adverse trends towards declining innovation and rising costs of drug development over the last several decades. Therapeutics for cardiovascular diseases (CVD) appear to have been particularly sensitive to these trends. Thirty-three percent fewer CVD therapeutics were approved between 2000 and 2009 compared to the previous decade, and the number of CVD drugs starting all clinical trial stages declined in both absolute and relative numbers between 1990 and 2012. In the last 5 years, drugs to treat CVD disease comprised just 6% of all new drug launches. This review discusses the decline in CVD therapeutics, the reasons behind it, and ways in which this trend is being or might be addressed. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 29% |
Spain | 1 | 14% |
Netherlands | 1 | 14% |
Unknown | 3 | 43% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 57% |
Science communicators (journalists, bloggers, editors) | 2 | 29% |
Scientists | 1 | 14% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 82 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 15 | 18% |
Researcher | 14 | 17% |
Student > Master | 9 | 11% |
Student > Ph. D. Student | 6 | 7% |
Student > Doctoral Student | 2 | 2% |
Other | 7 | 9% |
Unknown | 29 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 13% |
Biochemistry, Genetics and Molecular Biology | 9 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 9% |
Engineering | 7 | 9% |
Agricultural and Biological Sciences | 5 | 6% |
Other | 15 | 18% |
Unknown | 28 | 34% |